Stockreport

Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer

Seagen Inc.  (SGEN) 
Last seagen inc. earnings: 4/30 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.seattlegenetics.com
PDF -HER2CLIMB Trial Met Primary Endpoint and Both Key Secondary Endpoints- -Global Regulatory Strategy Includes NDA Submission to U.S. FDA Planned for First Quarter of 2020 [Read more]